Does simvastatin inhibit C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products?
CRP-induced CD32 expression and NF-kappaB activation were attenuated by simvastatin. A decrease in mevalonate and subsequent GGPP contributes to the inhibitory effects of simvastatin. These findings may provide an explanation of using statins on patients with high serum CRP levels.
All tested abutments have the potential to withstand physiologic occlusal forces in the anterior region (> 200 N). The applicability of the results to other implant systems should be verified.